Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.
The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group, and Oriza Holdings.
Accro Bioscience plans to use the proceeds from the financing to fund the Phase IIb clinical trial of AC-101, an RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for inflammatory and autoimmune diseases.
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Galapagos and Gilead expand collaboration to advance T cell engager programme
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing
Immunic granted European patent for vidofludimus calcium dosing regimens
Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Akeso's AK139 Phase II clinical trials approved in China
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals